Zymo Research is a globally established biotechnology company and industry leader in the fields of epigenetics, microbiomics and the emerging Next-Gen Sequencing space. With international facilities and a global distribution network, Zymo Research enables researchers in academia and the biomedical field to make cutting-edge discoveries all over the world. While the company provides some of the most technologically advanced products in the industry, everything is driven by the fundamental belief that “the beauty of science is to make things simple.”
Van Heron Labs
. | Van Heron Labs (VHL) The Cellular Intelligence Layer for Life Sciences Booth #1611 | vanheronlabs.com | contact@vanheronlabs.com — Van Heron Labs is transforming how biological processes are designed, optimized, and scaled. VHL has built the most powerful cellular intelligence engine ever created — the only end-to-end, multi-omic digital twin platform designed exclusively for cellular optimization. At the core of VHL’s platform is a proprietary system that decodes complete cellular biology — gene expression, metabolism, stress responses, and biomolecular needs across 17 molecular categories spanning thousands of compounds — and translates that data into a real-time biological digital twin. VHL identifies and predicts the impact of every critical biomolecule: metabolites, ions, trace metals, minerals, cofactors, growth factors, cytokines, ECM components, and more. The result: VHL customers see breakthrough improvements in titer, viability, potency, and manufacturability — faster and at a fraction of the cost of traditional R&D. Proven across cell therapy, biologics, precision fermentation, and more: T cell therapies (CD4/CD8, TIL, Treg): 80% improved viability, 40% increase in activation, FOXP3 stability for greater potency — saving $25K–$60K per batch iPSC programs: ~25 critical ingredients identified, many absent from any commercial media — 10X cheaper than internal R&D, 5 months faster to clinic MSC programs: ~30 critical ingredients identified, resolving stress pathways and improving scale-up reliability — unlocking $25–80M in potential new media product revenue HEK / bioprocessing: 40–200% proliferation improvement, 900% cell density gains with process optimization, 360% higher protein titer Microbial (E. coli, B. subtilis, P. aeruginosa): 200–400% proliferation increases, 200–360% higher titer, fully defined bioreactor media. How you can work with VHL: VHL offers four flexible engagement models — Analytics Only (1-week turnaround), Process Development Recommendations (1–2 weeks), Co-Development (3–10 weeks), and Strategic Partnerships for long-term innovation. All engagements begin with RNA-Seq or proteomics data and deliver interactive, publication-quality multi-omics reports, biological digital twins, and actionable recommendations your team can execute immediately. Backed by NVIDIA, Microsoft, and AWS, and trusted by dozens of life science companies, large and small. Who we’re looking to meet at BIO 2026: VHL is actively seeking strategic partnerships with CDMOs, CROs, reagent and culture media manufacturers, and asset-focused companies looking to improve manufacturing performance, reduce R&D burden, develop proprietary formulations, and unlock new revenue streams through the power of cellular intelligence. Want to connect before San Diego? Schedule a meeting or platform demo with CEO & Founder Rebecca Vaught, Ph.D. at calendly.com/rvaught-vanheronlabs/30min — or stop by Booth #1611 and meet us in person. We’d love to show you what cellular intelligence can do for your program.
Phase Clinical Services
Your complete resource for oncology clinical trials and biospecimens | Phase Clinical Services is a biospecimen provider headquartered in the New York area which specializes in science-driven and large-scale projects. Utilizing our global network of collection sites, we provide a wide range of materials, such as tumor tissue, blood products, FFPE blocks, cell preparations (e.g. PBMCs, CD34 cells), bulk plasma etc. We cover indications for oncology, infectious diseases, autoimmune conditions, many other disorders, as well as healthy volunteer studies. Our clients are pharma and biotech companies from startup to the top-ten level, assay developers, high-end academic institutions, and the U.S. government. We maintain an FDA-registered cell isolation lab in Milwaukee and an in-house pathology service. | Phase Clinical Services is a biospecimen provider headquartered in the New York area which specializes in science-driven and large-scale projects. Utilizing our global network of collection sites, we provide a wide range of materials, such as tumor tissue, blood products, FFPE blocks, cell preparations (e.g. PBMCs, CD34 cells), bulk plasma etc. We cover indications for oncology, infectious diseases, autoimmune conditions, many other disorders, as well as healthy volunteer studies.
Pharmigene Inc
Established in 2005, Pharmigene Inc. is a leading biotechnology company specializing in pharmacogenomic testing. We hold exclusive global licenses from Academia Sinica for patents related to genetic testing for Warfarin and other critical medications such as Carbamazepine and Allopurinol. Leveraging these proprietary technologies, we have developed advanced diagnostic products and tools that have secured comprehensive technical patent certifications across numerous countries worldwide, including the USA, Europe, New Zealand, Australia, Japan, China, India, and Southeast Asia.Headquartered in Taiwan, Pharmigene operates a state-of-the-art R&D center and maintains stringent quality management systems. Our commitment to excellence is underscored by our certifications, including international ISO 13485, Taiwan QMS (GMP), and South Korea KGMP, ensuring the highest standards in medical device manufacturing and diagnostic solutions.
iRepertoire
Over the past decade, iRepertoire has developed gold standard technologies for immune repertoire sequencing. Our core technologies provide the ability to amplify expressed V(D)Js in B or T cells, and we offer the only technology that can measure all 7 immune chains simultaneously. We also offer a single cell solution to capture V(D)J rearrangements from rare cell populations. Beyond sequencing, iRepertoire now provides comprehensive data analysis services that accelerate biomarker discovery, advance disease research, and support IO drug development programs. iRepertoire is committed to creating cutting-edge technology and analytical solutions that adapt to the ever-changing immune sequencing landscape. | .
Instant NanoBiosensors Co. Ltd
Instant NanoBiosensors (INB) is an innovative precision medicine company specializing in ultra-sensitive protein-based blood tests for Alzheimer’s disease and gene-based solutions for leukemia through its INLab NGS Solution. Revolutionizing Alzheimer’s Diagnostics Leveraging our proprietary Fiber Optic Particle Plasmon Resonance (FOPPR™) technology, we provide a non-invasive, rapid, and cost-effective solution for the early detection of Alzheimer’s-related biomarkers. Our technology enhances diagnostic accuracy, accelerates drug development, and supports personalized medicine applications for medical institutions and pharmaceutical companies. INB is the only point-of-care testing (POCT) platform on the market that enables end-to-end solutions—from antibody analysis to ultra-sensitive assay development. This platform has been adopted by the EU-funded TAuimMunE (TAME) project as a key training tool for PhD researchers. Current blood biomarker diagnostic methods are often expensive, centralized, and require specialized personnel to operate. INB’s solution addresses these limitations by making early Alzheimer’s detection more accessible and affordable. Our goal is to provide a highly accessible and precise diagnostic platform that enhances patient care and therapeutic outcomes worldwide. Leukemia Precision Medicine: INLab NGS Solution In leukemia diagnostics, INB has developed a comprehensive NGS Precision Medicine Solution that streamlines the entire workflow—from sample processing to final report generation—with fully integrated instruments, reagents, and software. We have extensive experience collaborating with National Taiwan University Hospital, working closely with hematology and oncology specialists to develop clinically relevant diagnostic reagents. Our solution currently serves nearly 70% of leukemia patients in Taiwan and has also been adopted by Yale Medical Center in the United States. Key Advantages of Our Solution ✅ Enhanced Accuracy and Efficiency: Our proprietary DimerOff™ technology minimizes primer dimer formation and sequencing noise, producing cleaner, more accurate sequencing data. This significantly improves sensitivity for detecting MDS/AML-related mutations, ensures higher clinical reliability, reduces sequencing costs by more than 50%, and shortens the turnaround time to just three days. ✅ MRD Detection & MPN Monitoring: Our solution enables precise monitoring of measurable residual disease (MRD) and myeloproliferative neoplasms (MPN), supporting long-term patient management and treatment adjustments. ✅ Customizable Panels for Specific Clinical Needs: We work closely with clinicians and researchers to develop NGS panels tailored to specific research and diagnostic requirements. Our flexible approach optimizes mutation detection, enhances patient stratification, and reduces operational costs for both research and clinical applications. Through continuous innovation and strategic partnerships, INB is committed to transforming precision medicine and improving patient outcomes worldwide. We Are Seeking Partnerships With: International Distributors interested in bringing our innovative diagnostic solutions to global markets. Biotech Companies looking for co-development opportunities in assay and panel development. Pharmaceutical Companies seeking companion diagnostics solutions to support targeted drug development. Hospitals & CROs aiming to establish a comprehensive precision medicine system within their organization. Scientists & Research Institutions interested in collaborative grant applications. If you are interested in collaborating with us, we welcome the opportunity to discuss how INB’s cutting-edge solutions can support your research, clinical, and commercial objectives.